Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)

Vincent Launay‐Vacher(Sorbonne Université), Ben Sprangers(KU Leuven), Matti Aapro(Clinique de Genolier), Gilbert Deray(Issy Media (France)), Benjamin D. Humphreys(Washington University in St. Louis), Hans Wildiers(KU Leuven), Florian Scotté(Université Paris-Saclay), Stuart M. Lichtman(Memorial Sloan Kettering Cancer Center), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Ezra E.W. Cohen(Moores Cancer Center), J-B Rey(Cancer Institute (WIA)), Margaret Dooley(International Network for Cancer Treatment and Research)
Annals of Oncology
March 4, 2015
10.1093/annonc/mdv136
Cited by 79

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Fate Tracing Reveals the Pericyte and Not Epithelial Origin of Myofibroblasts in Kidney Fibrosis
|American Journal Of Pathology|2009|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k